Journal
NEUROLOGICAL SCIENCES
Volume 41, Issue 9, Pages 2317-2324Publisher
SPRINGER-VERLAG ITALIA SRL
DOI: 10.1007/s10072-020-04541-z
Keywords
COVID-19; Alzheimer's dementia; Chronic lung disease; Coronavirus
Categories
Funding
- National Research Foundation of Korea - Korean government [NRF-2019M3E5D1A02068106]
Ask authors/readers for more resources
Introduction In the current study, we evaluated factors that increase the coronavirus disease (COVID-19) patient death rate by analyzing the data from two cohort hospitals. In addition, we studied whether underlying neurological diseases are risk factors for death. Methods In this retrospective cohort study, we included 103 adult inpatients (aged >= 18 years). We evaluated differences in demographic data between surviving and non-surviving COVID-19 patients. Results In a multivariate logistic analysis, age and the presence of chronic lung disease and Alzheimer's dementia (AD) were the only significant parameters for predicting COVID-19 non-survival (p < 0.05). However, hypertension, coronary vascular disease, dyslipidemia, chronic kidney disease, diabetes, and history of taking angiotensin II receptor blockers (ARBs) or angiotensin-converting enzyme (ACE) inhibitors, as well as nonsteroidal anti-inflammatory drugs (NSAIDs), were not significantly associated with the death of COVID-19 patients. The optimal cutoff value obtained from the maximum Youden index was 70 (sensitivity, 80.77%; specificity, 61.04%), and the odds ratio of non-survival increased 1.055 fold for every year of age. Conclusions Clinicians should closely monitor and manage the symptoms of COVID-19 patients who are over the age of 70 years or have chronic lung disease or AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available